Patient Success Stories


In January 2015, Jeff, a former U.S. National Swim Team member, discovered he had Stage IV lung cancer. The cancer had spread to 27 places in his body and he was given only 12 months to live. Jeff had a FoundationOne test which gave him a full genomic profile of his cancer and provided multiple targeted treatment options. Jeff and his oncologist ultimately decided to pursue a combination immunotherapy clinical trial, with very positive effects. Today, he’s back in the pool, as the University of Southern California’s assistant swim coach.


Corey was in college and enjoying running among other activities when she had a full body scan that revealed Stage IV lung cancer that had metastasized to her bones. Corey thought she would have to do chemotherapy, but wasn’t sure if it would work. Instead, her oncologist ordered a FoundationOne test, which identified a ROS1 alteration. Based on this alteration, Corey received the targeted therapy crizotinib. She has remained on this therapy, avoided side effects, and is back doing the activities she loves.


When Elizabeth was diagnosed with advanced stage lung cancer in April 2015, she was pregnant with her first child. She was told she had virtually no treatment options and had one year left to live. Elizabeth and her oncologist, Dr. Scott Laurie at the Ottawa Cancer Centre, decided to evaluate her cancer with FoundationOne. The test identified multiple alterations, including ROS1, which gave her multiple targeted therapy options. Elizabeth was initially treated with crizotinib and then followed up with lorlatinib as part of a clinical trial. She was then able to have surgery to remove the tumors. Elizabeth is involved in many advocacy efforts, and she hopes that her experience inspires more patients to get comprehensive genomic testing so they can have the opportunity to get targeted treatment options which could manage their disease. And her son Jack is doing great too.

>> Visit Elizabeth’s blog.


No one expects a marathon runner in her mid-forties to be diagnosed with lung cancer. But after Rebecca, a market executive and entrepreneur, was first diagnosed with an allergy to her cat in 2012 and prescribed Claritin for a persistent cough, an X-ray found a 12-centimeter tumor in the middle of her left lung — she had Stage III lung cancer. Rebecca’s treatment was informed by comprehensive genomic testing at Foundation Medicine. Three years later, she completed the 2015 New York City Marathon, her 14th marathon overall and first running with just one lung.